Terms: = Head and neck cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
434 results:
1. Lectin-like Transcript-1 (LLT1) Expression in Oral Squamous Cell Carcinomas: Prognostic Significance and Relationship with the Tumor Immune Microenvironment.
de Vicente JC; Lequerica-Fernández P; Rodrigo JP; Rodríguez-Santamarta T; Blanco-Lorenzo V; Prieto-Fernández L; Corte-Torres D; Vallina A; Domínguez-Iglesias F; Álvarez-Teijeiro S; García-Pedrero JM
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673902
[TBL] [Abstract] [Full Text] [Related]
2. Single cell analysis unveils B cell-dominated immune subtypes in HNSCC for enhanced prognostic and therapeutic stratification.
Li K; Zhang C; Zhou R; Cheng M; Ling R; Xiong G; Ma J; Zhu Y; Chen S; Chen J; Chen D; Peng L
Int J Oral Sci; 2024 Apr; 16(1):29. PubMed ID: 38622125
[TBL] [Abstract] [Full Text] [Related]
3. Integrating bulk and single-cell sequencing data to construct a Scissor
Cheng M; Xiong J; Liu Q; Zhang C; Li K; Wang X; Chen S
Cancer Immunol Immunother; 2024 Apr; 73(6):97. PubMed ID: 38619620
[TBL] [Abstract] [Full Text] [Related]
4. [Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
[No Abstract] [Full Text] [Related]
5. Verification of the expression trend and interaction prediction of innate immune cells and immune-checkpoint molecules in the process of oral mucosal carcinogenesis.
Li K; Shi L; Liu L; Wang J; Nie M; Liu X
Hua Xi Kou Qiang Yi Xue Za Zhi; 2024 Apr; 42(2):192-206. PubMed ID: 38597079
[TBL] [Abstract] [Full Text] [Related]
6. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
7. Immune checkpoint CD161/LLT1-associated immunological landscape and diagnostic value in oral squamous cell carcinoma.
Hu X; Dong Y; Xie S; Song Y; Yu C; He Y; Wang Z; Hu Q; Ni Y; Ding L
J Pathol Clin Res; 2024 Mar; 10(2):e353. PubMed ID: 38502058
[TBL] [Abstract] [Full Text] [Related]
8. Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences pd-l1 Expression in Papillary Thyroid Carcinoma.
Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
[TBL] [Abstract] [Full Text] [Related]
9. Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration.
Nakayama I; Ohashi M; Nunobe S
Chin Clin Oncol; 2024 Feb; 13(1):8. PubMed ID: 38453658
[TBL] [Abstract] [Full Text] [Related]
10. Perioperative immunotherapy for esophageal squamous cell carcinoma.
Wei DD; Fang JM; Wang HZ; Chen J; Kong S; Jiang YY; Jiang Y
Front Immunol; 2024; 15():1330785. PubMed ID: 38440724
[TBL] [Abstract] [Full Text] [Related]
11. A novel EIF3C-related CD8
Li R; Wang Y; Wen X; Cheng B; Lv R; Chen R; Hu W; Wang Y; Liu J; Lin B; Zhang H; Zhang E; Tang X
J Cancer Res Clin Oncol; 2024 Feb; 150(2):103. PubMed ID: 38400862
[TBL] [Abstract] [Full Text] [Related]
12. JunD-miR494-CUL3 axis promotes radioresistance and metastasis by facilitating EMT and restraining pd-l1 degradation in esophageal squamous cell carcinoma.
Li X; Cong J; Zhou X; Gao W; Li W; Yang Q; Li X; Liu Z; Luo A
Cancer Lett; 2024 Apr; 587():216731. PubMed ID: 38369005
[TBL] [Abstract] [Full Text] [Related]
13. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and sipd-l1 for synergistic targeted cancer treatment.
Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
[TBL] [Abstract] [Full Text] [Related]
14. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
[TBL] [Abstract] [Full Text] [Related]
15. HHLA2 is more significantly associated with poor prognosis in TSCC than pd-l1.
Li Y; Yang Q; Yang X; Ge J; Xu T; Liu H
J Oral Pathol Med; 2024 Feb; 53(2):159-168. PubMed ID: 38321252
[TBL] [Abstract] [Full Text] [Related]
16. Clinical significance of integrin αV and β superfamily members and focal adhesion kinase activity in oral squamous cell carcinoma: a retrospective observational study.
Sakurai S; Ishida Y; Shintani T; Yamasaki S; Matsui K; Hamana T; Nobumoto T; Yanamoto S; Hayashido Y
Pathol Oncol Res; 2024; 30():1611571. PubMed ID: 38312516
[No Abstract] [Full Text] [Related]
17. Prognostic role of pd-l1 expression in head and neck squamous cell carcinoma: An institutional experience from India.
Kala PS; Thapliyal N; Pant B; Sharma N; Pandey HS
Pathol Res Pract; 2024 Feb; 254():155133. PubMed ID: 38306860
[TBL] [Abstract] [Full Text] [Related]
18. Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus.
Porschen R; Fischbach W; Gockel I; Hollerbach S; Hölscher A; Jansen PL; Miehlke S; Pech O; Stahl M; Vanhoefer U; Ebert MPA
United European Gastroenterol J; 2024 Apr; 12(3):399-411. PubMed ID: 38284661
[TBL] [Abstract] [Full Text] [Related]
19. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
[TBL] [Abstract] [Full Text] [Related]
20. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.
Hosonuma M; Hirasawa Y; Kuramasu A; Murayama M; Narikawa Y; Toyoda H; Baba Y; Isobe J; Funayama E; Tajima K; Shida M; Hamada K; Tsurui T; Ariizumi H; Ishiguro T; Suzuki R; Ohkuma R; Kubota Y; Horiike A; Sambe T; Tsuji M; Wada S; Kiuchi Y; Kobayashi S; Tsunoda T; Yoshimura K
Cancer Sci; 2024 Mar; 115(3):752-762. PubMed ID: 38254257
[TBL] [Abstract] [Full Text] [Related]
[Next]
